5 GI events like nausea, diarrhea, constipation, vomiting, and dyspepsia were the most frequently reported adverse effects
Identifying Modifiable Factors Before Labeling Treatment Failure Before labeling a patient as a true non-responder, clinicians should carefully assess modifiable factors
The pharmacy benefit manager Prime Therapeutics published an analysis last summer that highlights this ongoing challenge with respect to the real-world effectiveness over time of the GLP-1 drugs used to treat obesity: Most overweight or obese patients without diabetes stop treatment within the first few years
Studies show that inulin can contribute to a lower glycemic and insulinemic response, which is linked to improved satietymeaning people often feel satisfied sooner and stay satisfied longer
doi: 10.1186/s40168-024-01964-0 121 ZhouWWuWSiZLiuHWangHJiangHet al
They share a common therapeutic value: improved glycaemic control, weight reduction, and protection against cardiovascular and renal outcomes
